「decision」の検索結果

Cross-method decision tree for calling hits in pooled CRISPR screens. Catalogs statistical models (MAGeCK RRA, MAGeCK MLE, BAGEL2, drugZ, JACKS, Chronos, CERES), experimental designs each is built for, failure modes outside design domain, reconciliation when methods disagree, multiple-testing and effect-size thresholds, the order of operations (count -> QC -> CN-correct -> hit-call -> validate), the second-best-sgRNA conservative rule, and consensus-hit strategy. Use when choosing among MAGeCK / BAGEL2 / drugZ / JACKS / Chronos for a given design, reconciling disagreement across two or three methods on the same screen, deciding whether to require consensus, gating downstream validation by hit-confidence tier, or interpreting unstable hit lists across reruns.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes pooled CRISPR screens with MAGeCK (Li et al 2014), covering count generation (mageck count), the RRA two-condition workflow (mageck test using alpha-RRA over per-sgRNA negative-binomial p-values), the MLE multi-condition workflow (mageck mle with explicit design matrix and beta-score output), normalization choice (median vs total vs control-sgRNA vs spike-in), sgRNA efficiency injection, paired-sample testing, time-course design, drug-screen versus dropout-screen design matrices, MAGeCKFlute and MAGeCK-VISPR downstream visualization, and decision logic for when to use MAGeCK vs JACKS / BAGEL2 / drugZ / Chronos. Use when running a fresh CRISPR screen analysis, picking RRA vs MLE for the experimental design, choosing a normalization method from QC signatures, debugging MLE convergence failure or NaN beta scores, comparing MAGeCK output across tools, or building a batch-aware multi-cell-line / multi-condition MLE design matrix.

日本語の概要は準備中です。原文の説明を表示しています。

Query protein-protein and gene interaction databases (STRING, BioGRID, IntAct, SIGNOR, Reactome, HuRI, HuMAP, OmniPath, ConsensusPathDB, DIP). Use when building PPI networks, choosing between physical vs functional vs genetic interactions, signed/directed vs undirected, high-throughput vs curated, picking confidence thresholds, aggregating across resources, or navigating license constraints. Encodes the database decision matrix, STRING v12 channel semantics, OmniPath as meta-database, SIGNOR for signed signaling, and per-resource rate limits.

日本語の概要は準備中です。原文の説明を表示しています。

Build clustered heatmaps for expression matrices and other features-by-samples data with rigorous distance/linkage/scaling choices, robust color mapping, optimal leaf ordering, and ComplexHeatmap/pheatmap/seaborn rendering. Covers the ward.D vs ward.D2 trap, the row-vs-column scaling decision, multi-track annotations, oncoPrint, and raster rendering for large matrices. Use when visualizing expression patterns across samples or identifying co-regulated clusters.

日本語の概要は準備中です。原文の説明を表示しています。

Build volcano and MA plots from differential-expression / association results with LFC shrinkage, FDR-adjusted thresholds, sensible label placement, and axis-truncation conventions. Covers EnhancedVolcano, ggplot2, matplotlib, and the apeglm/ashr/normal shrinkage decision. Use when visualizing differential-expression results (RNA-seq, ChIP-seq, ATAC-seq, proteomics) or any per-feature effect-size + p-value table.

日本語の概要は準備中です。原文の説明を表示しています。

Extracts and assigns COSMIC v3.4 mutational signatures (84 SBS / 11 DBS / 18 ID / 24 CN / 16 SV) from somatic VCFs using SigProfilerSuite, MutationalPatterns, MuSiCal mvNMF, SigNet, or HRDetect. Use when characterizing DNA-damage etiology (BRCA1/2 HRD, MMR-D, POLE, APOBEC3A, UV, tobacco, aflatoxin, 5-FU/SBS17b, platinum, colibactin SBS88), routing PARP inhibitor decisions, or auditing de novo extraction vs refit choice for cohort size.

日本語の概要は準備中です。原文の説明を表示しています。

Applies ACMG/AMP 2015 framework with ClinGen SVI specifications, Tavtigian 2018/2020 Bayesian point system, Abou Tayoun 2018 PVS1 decision tree, Pejaver 2022 calibrated PP3/BP4 thresholds for REVEL/BayesDel/AlphaMissense, Brnich 2020 PS3/BS3 OddsPath, Walker 2023 SpliceAI splicing framework, and AMP/ASCO/CAP 2017 tumor tiers. Use when classifying germline variants P / LP / VUS / LB / B, applying VCEP-specific CSpec rules, computing Whiffin BS1, or assigning cancer Tier I-IV per Li 2017.

日本語の概要は準備中です。原文の説明を表示しています。

Prioritizes rare-disease variants from trio/quad WES/WGS with de novo (DeNovoGear, Triodenovo), compound-heterozygous phasing (WhatsHap), mosaic VAF tiering, phenotype-driven ranking (Exomiser, Phen2Gene, AMELIE), ClinGen gene-disease validity gating, and ACMG SF v3.2 secondary findings reporting. Use when running diagnostic exome / genome pipelines, identifying candidate Mendelian disease genes, screening for incidental findings, or auditing VUS reclassification cycles. The ACMG/AMP classification framework (PVS1 decision tree, Pejaver PP3/BP4 calibration, Tavtigian point system) is in clinical-databases/acmg-classification.

日本語の概要は準備中です。原文の説明を表示しています。

Generates 3D conformer ensembles using RDKit ETKDGv3 with knowledge-enhanced distance geometry, MMFF94/UFF force-field optimization, CREST + GFN2-xTB semi-empirical refinement, and macrocycle-aware torsion preferences. Provides explicit decision rules for single vs ensemble conformer use, RMSD pruning, energy windows, conformer count, and force-field choice. Use when preparing 3D ligands for docking, generating descriptor input for 3D QSAR, or sampling macrocycle/peptide conformational ensembles.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes alternative splicing at single-cell resolution. The first decision is library chemistry — 10X 3' is fundamentally limited (RT primes from poly-A, R2 falls in 3' UTR, <0.1 junction read per cell per AS event). Plate-based full-length methods (Smart-seq3, FLASH-seq, VASA-seq, STORM-seq) and single-cell long-read (MAS-Iso-seq, scISOr-Seq2) are the chemistries that give per-cell isoform structure. Tools include MARVEL (R, Smart-seq integrated), BRIE2 (Bayesian PSI with regulatory features and ELBO_gain test), scQuint (junction-cluster, plate-based; not for 10X), SpliZ (annotation-free Z-score), Psix (graph-smoothness regulated AS), and Sierra (alternative polyadenylation, often confused with AS). Use when analyzing isoform usage in scRNA-seq, identifying cell-type-specific splicing, or determining whether scRNA-seq chemistry supports splicing analysis at all.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a carrier asks whether to buy or lease their next tractor (or trailer), comparing full-service lease (Ryder, Penske, NationaLease), capital lease, finance lease, walk-away open-end lease, or cash purchase. Covers tax treatment, residual risk, maintenance bundling, balance-sheet impact, and cash-flow modeling.

日本語の概要は準備中です。原文の説明を表示しています。

Audit an existing Coval evaluation setup for coverage, misleading scores, missing evidence, judge validation and execution risk. Read-only; use when inheriting an eval or deciding whether its results support a release decision.

日本語の概要は準備中です。原文の説明を表示しています。

Decision-ready scouting record for a user-connected provider access campaign. Use when an assigned Provider Access Launch task needs its easiest official route, minimum scopes, cost, account needs, approval path, implementation consumer, and easy-execute verdict established before submission. NOT for client Local Listings distribution.

日本語の概要は準備中です。原文の説明を表示しています。

When the user wants to apply psychological principles, mental models, or behavioral science to marketing. Also use when the user mentions 'psychology,' 'mental models,' 'cognitive bias,' 'persuasion,' 'behavioral science,' 'why people buy,' 'decision-making,' or 'consumer behavior.' This skill provides 70+ mental models organized for marketing application.

日本語の概要は準備中です。原文の説明を表示しています。

Claude Codeセッション中に行われたアーキテクチャ上の意思決定を構造化されたADRとして記録する。意思決定の瞬間を自動検出し、コンテキスト、検討された代替案、根拠を記録する。将来の開発者がコードベースの形状の理由を理解できるようADRログを維持する。

Analyze an idea, proposal, change, claim, or decision from facts through problem, value, mechanism, consequences, evidence, alternatives, and action. Use when the user asks what something is for, why it matters, whether it is worth doing, what impact it has, or how to decide. Do not use for simple factual lookup or straightforward execution.

日本語の概要は準備中です。原文の説明を表示しています。

Combine React's official "You Might Not Need an Effect" guidance with this project's stricter no direct useEffect stance. Use when writing, reviewing, or refactoring React components that might reach for useEffect, derived state, event relays, reset logic, subscriptions, or client fetching.

日本語の概要は準備中です。原文の説明を表示しています。

PHP Standards Recommendations (PSR) overview knowledge base. Provides comprehensive reference for all accepted PSRs including PSR-1,3,4,6,7,11,12,13,14,15,16,17,18,20. Use for PSR selection decisions and compliance audits.

日本語の概要は準備中です。原文の説明を表示しています。

GRASP principles knowledge base for PHP 8.5 projects. Provides quick reference for 9 responsibility assignment patterns (Information Expert, Creator, Controller, Low Coupling, High Cohesion, Polymorphism, Pure Fabrication, Indirection, Protected Variations). Use for architecture audits and design decisions.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze context and decide on continuation via Stop hook. Use when determining if work should continue, analyzing completion status, making continuation decisions, or implementing the Two-Claude pattern.

日本語の概要は準備中です。原文の説明を表示しています。

Apply 37signals/DHH Rails conventions when writing Ruby on Rails code. Use when building Rails applications, reviewing Rails code, or making architectural decisions. Covers various aspects of Rails application architecture, design and dependencies.

日本語の概要は準備中です。原文の説明を表示しています。

[51] EXECUTE. Commitment to maximum quality work with 150% coverage. Use when you need the highest quality output for critical tasks, complex problems, important decisions, or when standard work isn't enough. Triggers on "maximum quality", "150% mode", "full quality", "critical task", or when you explicitly want AI to work at its best.

日本語の概要は準備中です。原文の説明を表示しています。

Apply timeless programming wisdom from "97 Things Every Programmer Should Know" when writing, reviewing, or refactoring code. Use for design decisions, code quality checks, professional development guidance, testing strategies, and workflow optimization.

日本語の概要は準備中です。原文の説明を表示しています。

[32] ANALYZE. Ensure every critical claim has verifiable evidence with confidence levels. Each fact must have source + confidence percentage. If confidence <85%, enter Loop150 to find more sources. Use for critical decisions, factual claims, legal/compliance work, or any situation where unverified claims are dangerous.

日本語の概要は準備中です。原文の説明を表示しています。